China Business Law Journal: Cancer Drug Firm Adlai Nortye Raises USD97.5m in Nasdaq IPO
October 6, 2023
O’Melveny represented Adlai Nortye Ltd. in its IPO on the Nasdaq. Adlai Nortye expects to receive aggregate gross proceeds of US$97.5 million, including US$57.5 million from public offering and US$40 million from the concurrent private placement. The O’Melveny team was led by corporate partners Ke Geng, Vincent Lin, Ke Zhu, and Rob Plesnarski.
Read the full article here.